@ASigmundMD
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- Web
Account-level information from X, not a live location or the device used for a specific post.
Assistant Professor in Lymphoma @OSUHematology. @NUFeinbergMed alum. Interested in #lymsm #MedEd #WomenInMedicine #HemeSurvivorship. Views are my own.
Columbus, OH
Joined September 2014
- Tweets488
- Following250
- Followers356
- Likes475
Audrey Sigmund retweeted
Proud to share our @ASH_hematology @BloodPortfolio manuscript, led by my trainee Dr. @vpizzuti44 @CUInternalMed.
Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵
doi.org/10.1016/j.bneo.2026.…
Audrey Sigmund retweeted
End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
Interested in #Hematology?🩸
Join the @ASH_hematology Horizons in Hematology Group—a FREE online community designed to engage, inform, and inspire medical students & junior residents exploring careers in the field🩺
Sign up here:
ashconnections.hematology.or…
Audrey Sigmund retweeted
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial - The Lancet thelancet.com/journals/lance…
Audrey Sigmund retweeted
Prebiopsy steroids & diagnostic yield in DLBCL #lymsm
- 320 pts
- diagnostic yield unchanged w/ steroids (83% vs 81%)
- no association w/ dose or duration
- no delay in time to treatment
- FNA way less diagnostic than excisional/incisional
- Core needle 12% less likely to be diagnostic
Useful real-world data for pts needing steroids before diagnosis
jamanetwork.com/journals/jam…
Audrey Sigmund retweeted
🚨Just out in @BrJHaem
Hodgkin lymphoma's new era: choosing between Nivo-AVD and BrECADD
We compare and contrast HD21 & SWOG1826, attempting to be as neutral and objective as possible
Which would you choose?
onlinelibrary.wiley.com/doi/… #lymsm @mike_dickinson1
Audrey Sigmund retweeted
Imposter Syndrome, Burnout, and Maladaptive Perfectionism Among Oncology Professionals: A Global Cross-Sectional Study.
Read the full article. bit.ly/4d5cW3G
Audrey Sigmund retweeted
TOMORROW we’re launching our DLBCL webinar series!
Join @PallawiTorkaMD and Emily Ayers as they tackle treatment decisions in older patients — a conversation we all need in real-world practice.
Register at the link below and save your spot! us06web.zoom.us/webinar/regi…
Audrey Sigmund retweeted
Join the #BrighamBEI for Leadership in #MedEd, a new 4 part series for medical educators looking to build leadership skills, think strategically, and advance their careers. Kicks off April 8!
Register: bit.ly/BEI_Leadership
@BrighamFellows
@BrighamRadOnc
@harvardneuromds
Audrey Sigmund retweeted
Zanwar et al - POD24 in WM.
• 253 pts all Rx with 1L BR
• 5y PFS / OS 65% / 87%
• CXCR4 mutn worse prog (med PFS 3.3 v 8.8y
• POD24 (11%) assoc inf OS 71 v 86%
Not surprising but good to have data.
#lymsm
ashpublications.org/bloodadv…
Audrey Sigmund retweeted
💬 Viewpoint: Mass abstract submissions in #MedEd have led to inflated metrics, less meaningful research, and misaligned incentives for trainees and institutions.
ja.ma/4qlJES1
ALT JAMA viewpoint article titled "Abstract Factory—Research Culture Harming Medical Education" by Samer Al Hadidi et al., published online December 18, 2025. The article discusses the impact of mass abstract submissions on medical education.
Audrey Sigmund retweeted
Y Wang et al - ritux Maint after 1L BR in MCL
• 703 pts with ORR to 1L BR at 3mo post
• retrospect
• 56% R Mx, 44% no Mx (similar features)
• landmark analy: med EFS 49.9 mo with Mx, 29.7mo without, also OS benefit.
Confirms role of MxR in MCL
#lymsm
ashpublications.org/bloodadv…
Audrey Sigmund retweeted
The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ASH_hematology
Audrey Sigmund retweeted
Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it.
Read the review “Strategies to Reinvigorate the Bedside Clinical Encounter,” the latest in the Medical Education series, by Brian T. Garibaldi, MD, MEHP, and Stephen W. Russell, MD, from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews): nej.md/4nUirnP
ALT Review Article | Medical Education Strategies to Reinvigorate the Bedside Clinical Encounter An illustration describing a scenario with a patient, a resident, and a medical educator
Audrey Sigmund retweeted
Learn more about clinical outcomes with a treatment option for 3L+ DLBCL adult patients. Click here hubs.ly/Q03S3vC30 to discover clinical trial efficacy, safety data, dosing, monitoring & management considerations for select adverse reactions, and more.
Audrey Sigmund retweeted
Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…
Audrey Sigmund retweeted
Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma aacrjournals.org/clincancerr…
Audrey Sigmund retweeted
Optimising treatment strategies in older patients with mantle cell lymphoma - The Lancet thelancet.com/journals/lance…
Audrey Sigmund retweeted
Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? ashpublications.org/blood/ar…
Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer
